Puma Biotechnology (NASDAQ:PBYI) Posts Earnings Results, Beats Estimates By $0.12 EPS

Puma Biotechnology (NASDAQ:PBYI) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12, FiscalAI reports. The business had revenue of $54.48 million during the quarter, compared to analysts’ expectations of $51.00 million. Puma Biotechnology had a return on equity of 53.15% and a net margin of 20.38%. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Puma Biotechnology Stock Up 22.2%

NASDAQ PBYI traded up $1.09 on Friday, reaching $5.99. The company had a trading volume of 2,366,087 shares, compared to its average volume of 490,998. The company’s fifty day moving average is $5.02 and its 200-day moving average is $4.11. The firm has a market capitalization of $301.72 million, a price-to-earnings ratio of 6.11 and a beta of 1.35. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.62 and a current ratio of 1.73. Puma Biotechnology has a 1-year low of $2.32 and a 1-year high of $6.07.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings cut Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PBYI. Evergreen Capital Management LLC acquired a new stake in Puma Biotechnology in the 2nd quarter valued at approximately $329,000. Bridgeway Capital Management LLC boosted its position in Puma Biotechnology by 150.0% during the 2nd quarter. Bridgeway Capital Management LLC now owns 202,790 shares of the biopharmaceutical company’s stock worth $696,000 after acquiring an additional 121,690 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Puma Biotechnology during the 2nd quarter worth approximately $135,000. Sei Investments Co. raised its holdings in shares of Puma Biotechnology by 11.4% in the second quarter. Sei Investments Co. now owns 347,234 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 35,573 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Puma Biotechnology in the second quarter worth $36,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.